Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PAR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PAR2 N-Terminal / Mutant Recombinant Protein (cleavage-resistant mutants). HEK293 expressed, high purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View PAR2 Products |
| Gene Delivery | PAR2 Promise-ORF / Lentivirus Particles. Full-length ORF with native glycosylation for stable GPCR cell line construction. Sequence Verified. | View PAR2 Products |
| Benchmark Ab | Anti-PAR2 Recombinant monoclonal (antagonist format) for positive control in blocking assays. Endotoxin Controlled. | View PAR2 Products |
| Validator | PAR2 siRNA Set. For knockdown verification in calcium flux and internalization assays. | View PAR2 Products |
| Related Target: F2R (PAR1) | Synergistic thrombotic/inflammatory pathway; critical for selectivity counter-screening. | View F2R Products |
| Related Target: TPSAB1 (Tryptase) | Primary physiological protease activator of PAR2. | View TPSAB1 Products |
| Related Target: F2RL3 (PAR4) | Platelet activation pathway; assess PAR-family cross-reactivity. | View PAR4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex GPCR Conformation & Conformational Integrity | Lentivirus Premade Particles for stable cell line construction; maintains 7-TM domain structure for native epitope presentation. |
| Cleavage Site Specificity | Sequence Verified N-terminal domains for precise epitope mapping; cleavage-resistant mutant proteins as negative controls. |
| Species Cross-reactivity (Cyno/Mouse/Human) | Ortholog lentivirus particles available; native glycosylation patterns preserved in HEK293 expression system. |
| PAR Family Selectivity (PAR1/PAR4 off-target) | Homolog panel proteins (PAR1, PAR3, PAR4) with strict sequence verification for counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies included. |
| False Positives | Validated siRNA included for specificity checks; cleavage-resistant mutant proteins as negative controls. |
Live PAR2/F2RL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Latest Antagonist Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for PAR2 therapeutics is intensifying, with major players shifting focus from traditional small molecules to monoclonal antibodies and allosteric modulators. As first-generation therapies for inflammatory pain and dermatological conditions reach the clinic, the next wave of R&D is targeting the tumor microenvironment and immune evasion mechanisms. The PAR2 inhibitor landscape is transitioning from broad anti-inflammatory applications to precision indications in neuropathic pain and metastatic cancer. With i2 Pharmaceuticals' I-340 and EMD Serono's EMD-256 advancing through Phase II, the industry is validating PAR2 as a druggable GPCR target beyond traditional anticoagulant paradigms. Next-wave biologics are exploring allosteric modulation and biased signaling strategies to overcome the receptor's promiscuous protease activation mechanism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | J&J, AstraZeneca, Astellas, Academic Consortia | Atopic Dermatitis, Asthma, Pancreatic Cancer, Fibrosis | Epitope Mapping (Need high-purity N-term peptides); Species Cross-reactivity (Human/Cyno/Mouse orthologs essential) |
| Small Molecule Antagonist | Mimetis, Boehringer, i2 Pharmaceuticals, EMD Serono, Bayer | Pain, Inflammation, Neuropathic Pain, IBD | Calcium Flux & Beta-arrestin assays (Need full-length GPCR cell lines) |
| Pepducin (Cell-penetrating) | Academic Spin-offs, UNC Chapel Hill (Research) | Oncology, Inflammation | Internalization Assays (Lentivirus-based stable reporter lines) |
| Biased Ligand | Novartis, Structure-based programs | Metastatic Breast Cancer | Pathway-selective screening (Mutant constructs for signaling bias) |
Molecular Differentiation & Assay Strategy
To achieve best-in-class PAR2 drugs, critical differentiation factors include: ultra-high affinity (Kd <1nM) to compete with tethered ligand activation; species cross-reactivity validation across human, cyno, and mouse orthologs; PAR family selectivity to avoid off-target effects on PAR1/PAR4; and conformational integrity maintained through lentivirus-based stable cell lines. Key assays include calcium flux for Gαq signaling, β-arrestin recruitment for biased signaling profiling, and epitope mapping using cleavage-resistant mutant proteins. TarMart provides lentivirus particles, mutant protein panels, and ortholog tools to support these workflows.